기본 통계
| CIK | 1783036 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NLS Pharmaceutics AG - Equity Warrant
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 27, 2026 |
Exhibit 99.1 NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) - NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therap |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) Hohstrasse 1, 8302 Kloten Switzerland (Address of principal executive office) Indicate by |
|
| May 11, 2026 |
As filed with the Securities and Exchange Commission on May 11, 2026 As filed with the Securities and Exchange Commission on May 11, 2026 Registration No. |
|
| May 11, 2026 |
CALCULATION OF FILING FEE TABLES NewcelX Ltd. Table 1: Newly Registered and Carry Forward Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 NewcelX Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common shares, par value |
|
| May 5, 2026 |
As filed with the Securities and Exchange Commission on May 5, 2026 As filed with the Securities and Exchange Commission on May 5, 2026 Registration No. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) Hohstrasse 1, 8302 Kloten Switzerland (Address of principal executive office) Indicate |
|
| April 30, 2026 |
Exhibit 99.1 NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long- |
|
| April 29, 2026 |
NewcelX Ltd. (the “Company”) CLAWBACK POLICY Effective as of April 27, 2026 Exhibit 97.1 NewcelX Ltd. (the “Company”) CLAWBACK POLICY Effective as of April 27, 2026 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Compensat |
|
| April 29, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by NewcelX Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem |
|
| April 29, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Omri Hagai, certify that: 1. I have reviewed this annual report on Form 20–F of NewcelX Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statement |
|
| April 29, 2026 |
STATUTEN NewcelX AG NewcelX SA NewcelX Ltd (die “Gesellschaft”) Exhibit 1.1 STATUTEN der NewcelX AG NewcelX SA NewcelX Ltd (die “Gesellschaft”) ARTICLES OF ASSOCIATION of NewcelX AG NewcelX SA NewcelX Ltd (the “Company”) I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 - Firma, Sitz, Dauer I. Name, Domicile, Duration and Purpose of the Company Art. 1 - Name, Domicile, Duration Unter der Firma NewcelX AG NewcelX SA NewcelX Ltd besteht mit Sitz in Kloten |
|
| April 29, 2026 |
Kadimastem Ltd. 2022 Share Incentive Plan Exhibit 4.1 Kadimastem Ltd. 2022 Share Incentive Plan Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1. Purpose. The purpose of this 2022 Share Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Providers of Kadimastem Ltd., an Israeli company (together with any successor co |
|
| April 29, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Twito, certify that: 1. I have reviewed this annual report on Form 20–F of NewcelX Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statemen |
|
| April 29, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: Registration Statement (Form F-3 Nos. 333-282788, 333-268690 and 333-269220) of NewcelX Ltd. of our report dated April 29, 2026, with respect to the consolidated financial statements of NewcelX Ltd. included in this Annual Report (Form F-20) o |
|
| April 29, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by NewcelX Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem |
|
| April 29, 2026 |
Exhibit 11.1 NEWCELX LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: April 27, 2026 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of NewcelX Ltd., a Swiss corporation (the “Company”), with respect to transactions in the Company’s securities. The Company has a |
|
| April 29, 2026 |
FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| April 29, 2026 |
Description of Rights of Each Class of Securities Exhibit 2.1 Description of Rights of Each Class of Securities Type and Class of Securities As part of the initial public offering of NewcelX Ltd. (formerly NLS Pharmaceutics Ltd.), or the Company, in February 2021 on the Nasdaq Capital Market, the Company conducted a share capital increase. As of February 5, 2021, the Company had a registered share capital of CHF 235,826.50 divided into 11,791,325 |
|
| April 20, 2026 |
Exhibit 99.2 A P R I L 2 0 2 6 ( N A S D A Q : N C E L ) © 2 0 2 6 N EW C EL X L TD . REGENERATIVE MEDICINE TO CURE TYPE 1 DIABETES Leading The Evolution of Type 1 Diabetes Cure With a Scalable Platform Producing Enriched, High - quality Stem Cell – derived Islets Disclaimer This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform A |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) Hohstrasse 1, 8302 Kloten Switzerland (Address of principal executive office) Indicate |
|
| April 20, 2026 |
Exhibit 99.1 NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) - NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today |
|
| April 1, 2026 |
COMMON SHARE PURCHASE WARRANT NEWCELX LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 1, 2026 |
Exhibit 99.1 NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 1, 2026— NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered |
|
| April 1, 2026 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NEWCELX LTD. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive office) Indicate |
|
| April 1, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2026, between NewcelX Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th |
|
| March 9, 2026 |
Exhibit 99.1 NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) to Advance NCEL-101 Program for Type 1 Diabetes Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 09, 2026 (GLOBE NEWSWIRE) - NewcelX Ltd. (“NewcelX”) (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Di |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 1) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive of |
|
| February 12, 2026 |
Exhibit 99.1 NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset Zurich, Switzerland — February 12, 2026 — NewcelX Ltd. (“NewcelX” or the “Company”) (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cel |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 1) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| January 29, 2026 |
Exhibit 99.2 JANUARY 2026 ( NASDAQ : NCEL ) ©2026 N EW C EL X L TD . REGENERATIVE MEDICINE TO CURE TYPE 1 DIABETES 72:$5'$&85()257<3( ',$%(7(6 Disclaimer This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws . For example, NewCelX Ltd . (“ NewCelX ,” “we,” “our” or “us”) is us |
|
| January 29, 2026 |
Exhibit 99.1 NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership team Zurich, Switzerland – January 29, 2026 — NewcelX Ltd. (NASDAQ: NCEL) (“NewcelX” or the “Company”), a clinical-stage cell therapy company advanci |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive office) Indicat |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 (Report No. 2) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| January 12, 2026 |
Exhibit 99.1 NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell–Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression Zurich, Switzerland – January 12th – NewcelX Ltd. (Nasdaq: NCEL) (“NewcelX” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today report |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 (Report No. 1) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| January 5, 2026 |
Exhibit 99.1 NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board Zurich, Switzerland and Ness Ziona, Israel – January 5th, 2026 – NewcelX Ltd. (Nasdaq: NCEL) (“NewcelX”), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 (Report No. 1) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| December 11, 2025 |
Exhibit 99.1 NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China Publication in key market advances NewcelX’s global IP strategy across Asia and supports the Company’s expanding position in neurology and metabolic diseases Zurich, Switzerland – December 11th – NewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced c |
|
| November 20, 2025 |
Exhibit 16.1 November 20, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by NEWCELX LTD (as successor to NLS Pharmaceutics Ltd) in its Form 6-K dated November 20, 2025. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of NEWCELX LTD |
|
| November 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 5) Commission file number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 (Report No. 4) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| November 17, 2025 |
Exhibit 99.1 NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute Zurich, Switzerland and Ness Ziona, Israel – November 17, 2025 – NewcelX Ltd. (Nasdaq: NCEL) (“NewcelX” or “the Company”), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative an |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 3) Commission file number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| November 6, 2025 |
As filed with the U.S. Securities and Exchange Commission on November 5, 2025. As filed with the U.S. Securities and Exchange Commission on November 5, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NewcelX Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisd |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 (Report No. 2) Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive |
|
| November 4, 2025 |
NewCelX CEO Issues Letter to Shareholders Exhibit 99.1 NewCelX CEO Issues Letter to Shareholders Zurich, Switzerland, November 4, 2025 - NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicine and neuroscience expertise within a unified platform, today issued a letter to its shareholders. |
|
| November 3, 2025 |
Exhibit 99.1 NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. Zurich, Switzerland, November 3, 2025 - NewcelX Ltd. (Nasdaq: NCEL) (“NewCelX” or the “Company”), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicin |
|
| November 3, 2025 |
Exhibit 99.2 INNOVATIVE THERAPIES TRANSFORMING LIVES N OVEMBER 2025 ( NASDAQ : NCEL ) ©2025 NewCelX Ltd. Disclaimer This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws . For example, NewCelX Ltd . (“ NewCelX ,” “we,” “our” or “us”) is using forward - looking statements when |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-39957 NEWCELX LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive office) Indica |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 8) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 30, 2025 |
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs Exhibit 99.1 NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs ● DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs ● Supported by Solid Cash Position and Strategic Funding Outlook Zurich, Switzerland – October 30, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS”), a Swiss clinical-stage biopharmaceutical company focused |
|
| October 30, 2025 |
Nlspw-form25 |
|
| October 30, 2025 |
Exhibit 99.1 NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol “NCEL” Zurich, Switzerland and Ness Ziona, Israel October 30, 2025 – NewcelX Ltd. (“NewCelX” or the “Company”) completed the previously announced merger transaction, pursuant to tha |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 9) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 29, 2025 |
STATUTEN NewcelX AG NewcelX SA NewcelX Ltd (die “Gesellschaft”) Exhibit 99.1 STATUTEN der NewcelX AG NewcelX SA NewcelX Ltd (die “Gesellschaft”) ARTICLES OF ASSOCIATION of NewcelX AG NewcelX SA NewcelX Ltd (the “Company”) I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 - Firma, Sitz, Dauer I. Name, Domicile, Duration and Purpose of the Company Art. 1 - Name, Domicile, Duration Unter der Firma NewcelX AG NewcelX SA NewcelX Ltd besteht mit Sitz in Kloten |
|
| October 29, 2025 |
Exhibit 99.2 NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem ZURICH, SWITZERLAND / ACCESSWIRE / October 29, 2025 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with r |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 7) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 6) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 29, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger Zurich, Switzerland – October 29, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS” or the “Company”), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 5) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 28, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem’s Shares Zurich, Switzerland and Ness Ziona, Israel – October 28, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”) and Kadimastem Ltd. (TASE: KDST) (“Kadimastem”) today announced that, following the receipt of Nasdaq’ |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 4) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 27, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger Zurich, Switzerland and Ness Ziona, Israel – October 27, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS”), a Swiss cli |
|
| October 24, 2025 |
As filed with the Securities and Exchange Commission on October 24, 2025 As filed with the Securities and Exchange Commission on October 24, 2025 Registration No. |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 3) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 23, 2025 |
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 Exhibit 99.1 NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 Zurich, Switzerland – October 23, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (“CNS”) disorders, and Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), an advanced clinical-st |
|
| October 17, 2025 |
As filed with the U.S. Securities and Exchange Commission on October 17, 2025. As filed with the U.S. Securities and Exchange Commission on October 17, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or ot |
|
| October 10, 2025 |
Kadimastem Ltd. Financial Statements as of December 31, 2024 Table of Contents Exhibit 99.2 Kadimastem Ltd. Financial Statements as of December 31, 2024 Table of Contents Page Report of Independent Registered Public Accounting Firm (PCAOB ID 1281) 2 Statements of Financial Position 3 Statements of Profit or Loss and Other Comprehensive Loss 4 Statements of Changes in Equity 5 Statements of Cash Flows 7 Notes to the Financial Statements 8 Kost Forer Gabbay & Kasierer Tel.: +9 |
|
| October 10, 2025 |
Kadimastem Ltd. & NLS Pharmaceutics Ltd. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 Kadimastem Ltd. & NLS Pharmaceutics Ltd. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information was prepared in accordance with Article 11 of Regulation S-X under the Securities Act of 1933, as amended. The following information and all other information contained in the Unaudited Pro Forma Condensed Combi |
|
| October 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 10, 2025 |
Kadimastem Ltd. Interim Condensed Financial Statements as of June 30, 2025 Table of Contents Exhibit 99.1 Kadimastem Ltd. Interim Condensed Financial Statements as of June 30, 2025 Unaudited Table of Contents Page Statements of Financial Position 2 Statements of Profit or Loss and Other Comprehensive Loss 3 Statements of Changes in Equity 4-6 Statements of Cash Flows 7-8 Notes to Interim Financial Statements 9-14 - - - - - - - - - - - - - - - - KADIMASTEM LTD. STATEMENTS OF FINANCIAL POSI |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offic |
|
| October 6, 2025 |
Exhibit 99.1 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page Interim Condensed Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 1 Unaudited Interim Condensed Statements of Operations and Comprehensive Loss f |
|
| October 6, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with our unaudited interim condensed financial statements and related notes as of and for the six months ended June 30, 2025, included as Exhibit 99.1 to this Report on Form 6-K. This discussion and other parts of the interim report |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principa |
|
| September 30, 2025 |
X0101 EFFECT 33 LIVE 2025-09-30 16:00:00 F-1 0001783036 NLS Pharmaceutics Ltd. 333-290516 |
|
| September 30, 2025 |
Exhibit 99.1 NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company Zurich, Switzerland – September 30, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS”), a Swiss c |
|
| September 29, 2025 |
September 29, 2025 Alexander Zwyer Chief Executive Officer NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland Re: NLS Pharmaceutics Ltd. Registration Statement on Form F-1 Filed September 25, 2025 File No. 333-290516 Dear Alexander Zwyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests f |
|
| September 29, 2025 |
NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland September 29, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: NLS Pharmaceutics Ltd. (CIK 0001783036) Registration Statement No. 333-290516 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: NLS Pharmaceutics Ltd. (the “Registrant”) hereby request |
|
| September 25, 2025 |
As filed with the Securities and Exchange Commission on September 25, 2025 As filed with the Securities and Exchange Commission on September 25, 2025 Registration No. |
|
| September 25, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 NLS Pharmaceutics Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common shares, |
|
| September 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6, CH-8058 Zurich, Switzerland (Address of prin |
|
| September 19, 2025 |
Exhibit 16.1 September 19, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by NLS Pharmaceutics Ltd. in its Form 6-K dated September 19, 2025. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of NLS Pharmaceutics Ltd. contained therei |
|
| September 10, 2025 |
Exhibit 99.1 Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger Zurich, Switzerland and Ness Ziona, Israel – September 10, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS”), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (“CNS”) disorders, and Kadimastem Ltd. (TASE: KDST) (“Kadimaste |
|
| September 10, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284075 PROXY STATEMENT FOR EXTRAORDINARY SHAREHOLDERS’ MEETING OF NLS PHARMACEUTICS LTD. PROSPECTUS FOR UP TO 70,000,000 COMMON SHARES AND UP TO 70,000,000 PRE-FUNDED WARRANTS TO PURCHASE 70,000,000 COMMON SHARES OF NLS PHARMACEUTICS LTD. PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Shareholders of NLS Pharmaceutics Ltd.: You are cordiall |
|
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principa |
|
| September 9, 2025 |
X0101 EFFECT 33 LIVE 2025-09-09 16:00:00 F-4 0001783036 NLS Pharmaceutics Ltd. 333-284075 |
|
| September 4, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients - Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India - Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland China—including the Greater Bay Area—s |
|
| September 4, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission file number: 001-39957 NLS PHARMACEU |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive off |
|
| September 3, 2025 |
Exhibit 4.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between NLS PHARMACEUTICS LTD., and VSTOCK TRANSFER, LLC, as the Rights Agent Dated as of [*], 2025 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated [*], 2025 (the “Signing Date”), is by and between, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS”), and VStock Transfer, LLC, a California limited liabi |
|
| September 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on September 3, 2025. As filed with the U.S. Securities and Exchange Commission on September 3, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdicti |
|
| August 29, 2025 |
SEVENTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 SEVENTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Seventh Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of August 29, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerlan |
|
| August 29, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file number: 001-39957 N |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal e |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal e |
|
| August 6, 2025 |
Exhibit 99.1 Execution Version EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this “Agreement”), dated as of August 5, 2025, is entered into by and between NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”) and Alpha Capital Anstalt (the “Holder”). RECITALS WHEREAS, the Holder is the holder of a warrant dated October 10, 2024, to purchase 207,913 shares o |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive office |
|
| July 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 29, 2025. As filed with the U.S. Securities and Exchange Commission on July 29, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction o |
|
| July 18, 2025 |
SIXTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 SIXTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Sixth Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of July 18, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“Pa |
|
| July 18, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 18, 2025. As filed with the U.S. Securities and Exchange Commission on July 18, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction o |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| July 18, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 4) Commission file number: 001-39957 NLS |
|
| July 17, 2025 |
Exhibit 99.1 NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immuno |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| July 1, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| July 1, 2025 |
FIFTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 FIFTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Fifth Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of July 1, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“Par |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 30, 2025 |
Exhibit 99.4 June 26, 2025 Alpha Capital Anstalt Altenbach 8 9490 Vaduz, Liechtenstein Ladies and Gentlemen: Reference is made to that certain Securities Purchase Agreement, dated as of March 26, 2025 (the “Purchase Agreement”), by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and including any successor Company thereto (the “Company”) and each of the o |
|
| June 30, 2025 |
AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT Exhibit 99.2 AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT This Amendment to the Securities Purchase Agreement (this “Amendment”) is dated as of June 26, 2025, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”) and the purchasers identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and col |
|
| June 30, 2025 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 30, 2025 |
Exhibit 99.6 NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, Switzerland, June 30, 2025 – NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system ( |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 23, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 23, 2025. As filed with the U.S. Securities and Exchange Commission on June 23, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction o |
|
| June 16, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 3) Commission file number: 001-39957 NLS |
|
| June 16, 2025 |
NLS Pharmaceutics CEO Issues Letter to Shareholders Exhibit 99.1 NLS Pharmaceutics CEO Issues Letter to Shareholders ZURICH, June 16,2025 /PRNewswire/ - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders. Dear Shareholders, We are delighted to share a summary of NLS Pharmaceutics’ achi |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 (Report No. 2) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 10, 2025 |
[voting instructions and appendices follow] Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, June 6, 2025 Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invite you to |
|
| June 9, 2025 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.1 PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Warrant Shares: [] Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [] or its assigns (the “Holder”) |
|
| June 9, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 9, 2025. As filed with the U.S. Securities and Exchange Commission on June 9, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction of |
|
| June 9, 2025 |
Exhibit 10.36 July 17, 2024 (“Effective Date”) Kadimastem Ltd. Pinchas Sapir 7, Weizmann Science Park Nes-Ziona, Israel For the attention of: Executive Chairman & President Dear Mr. Twito, Agreement for the provision of Manufacturing services Kadimastem (TASE: KDST) (“Client”) is a bio-pharmaceutical company developing regenerative medicine therapies derived from Human Embryonic Stem Cells (hESCs) |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| June 6, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| June 6, 2025 |
FOURTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 FOURTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Fourth Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of June 5, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“P |
|
| May 16, 2025 |
Description of Rights of Each Class of Securities Exhibit 2.1 Description of Rights of Each Class of Securities Type and Class of Securities As part of the initial public offering of the NLS Pharmaceutics Ltd., or the Company, in February 2021 on the Nasdaq Capital Market, the Company conducted a share capital increase. As of February 5, 2021, the Company had a registered share capital of CHF 235,826.50 divided into 11,791,325 registered shares w |
|
| May 16, 2025 |
Exhibit 11(b) NLS PHARMACEUTICS LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: January 1st, 2024 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of NLS Pharmaceutics Ltd., a Swiss corporation (the “Company”), with respect to transactions in the Company’s secur |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Nicole Fernandez-McGovern, certify that: 1. I have reviewed this annual report on Form 20–F of NLS Pharmaceutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst |
|
| May 16, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (File Nos. 333-284696, 333-284811, 333-282788, 333-262489, 333-268690 and 333-269220) of NLS Pharmaceutics Ltd. of our report dated May 15, 2024, except for the effects of the reverse share split discussed in Note 2 to the consolidated |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by NLS Pharmaceutics Ltd. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with the requirem |
|
| May 16, 2025 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.2 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of NLS Pharmaceutics Ltd. On Forms F-3 (File Nos. 333-284696, 333-284811, 333-282788, 333-262489, 333-268690 and 333-269220) of our report dated May 16, 2025, with respect to our audit of the consolidated financial statements of NLS Pharmaceutics Ltd. for |
|
| May 16, 2025 |
FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Alexander Zwyer, certify that: 1. I have reviewed this annual report on Form 20–F of NLS Pharmaceutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| May 16, 2025 |
AMENDMENT NO. 2 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 4.28 AMENDMENT NO. 2 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment is made as of February 17, 2025 (this “Amendment”) to the Agreement of Merger and Plan of Reorganization, dated November 4, 2024 (as previously amended on January 30, 2025, the “Agreement”), between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“Kadimastem”), NLS Pharmaceutics |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by NLS Pharmaceutics Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with the requ |
|
| May 5, 2025 |
AMENDMENT NO. 3 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 AMENDMENT NO. 3 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment is made as of May 5, 2025 (this “Amendment”) to the Agreement of Merger and Plan of Reorganization, dated November 4, 2024 (as previously amended on January 30, 2025 and on February 17, 2025, the “Agreement”), between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“Kadimastem”) |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| May 1, 2025 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: May 31, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39957 CUSIP NUMBER H57830137 (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Perio |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal ex |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices |
|
| April 15, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| April 15, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl- Induced Reward in Animal Models Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy Zurich, Switzerland – April 15, 2025 – NLS Phar |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Add |
|
| April 4, 2025 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 31, 2025 |
Exhibit 99.5 NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement The equity financing is at a 10% premium to the market share price1 ZÜRICH, Switzerland, March 31, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for ce |
|
| March 31, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission file number: 001-39957 NL |
|
| March 31, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2025. As filed with the U.S. Securities and Exchange Commission on March 31, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal ex |
|
| March 31, 2025 |
COMMON SHARES PURCHASE AGREEMENT Exhibit 99.3 COMMON SHARES PURCHASE AGREEMENT This COMMON SHARES PURCHASE AGREEMENT is made and entered into as of March 28, 2025 (this “Agreement”), by and between Alpha Capital Anstalt, a Liechtenstein Anstalt (the “Investor”), and NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”). RECITALS WHEREAS, the parties desire that, upon the terms and subjec |
|
| March 31, 2025 |
PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES NLS PHARMACEUTICS LTD. Exhibit 99.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 31, 2025 |
Exhibit 10.18 Kadimastem Ltd. Registrar of Companies Number: 514192558 (the “Company”) Dated: 09/12/2021 Company: 6409 To: The National Authority for Technological Innovation RE: Letter of Commitment and Notice of Commencement of an Approved Program 1. We hereby sign this Letter of Commitment and Notice of Commencement of the Approved Program (hereinafter: the "Letter of Commitment") in relation t |
|
| March 31, 2025 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2025, by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland, with headquarters located at The Circle 6, 8058 Zurich, Switzerland (the “Company”), and the investors listed on the Schedule of Purchasers attached hereto (each, a “Purchaser” and col |
|
| March 31, 2025 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 26, 2025, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchas |
|
| March 31, 2025 |
Exhibit 10.13 LICENCE AGREEMENT by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED and KADIMASTEM LIMITED August 31, 2009 Ref.: 05-2753-09-18 No.: 113177-004 LICENCE AGREEMENT Between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and KADIMASTEM LIMITED a company duly registered u |
|
| March 10, 2025 |
NLS Pharmaceutics CEO Issues Letter to Shareholders Exhibit 99.1 NLS Pharmaceutics CEO Issues Letter to Shareholders ZÜRICH, Switzerland, March 10, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders. Dear Shareholders, We are thrilled to share the significant progress and strate |
|
| March 10, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices |
|
| March 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 28, 2025. As filed with the U.S. Securities and Exchange Commission on February 28, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdicti |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.6 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
Exhibit 4.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between NLS PHARMACEUTICS LTD., and VSTOCK TRANSFER, LLC, as the Rights Agent Dated as of November 4, 2024 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated November 4, 2024, is by and between, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS”), and VStock Transfer, LLC, a California limited liability co |
|
| March 3, 2025 |
BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT Exhibit 10.9 Execution Version BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT THIS BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) dated as of April 29, 2023 (the “Effective Date”), is entered into by and between Kadimastem Ltd., a public company formed and registered under the laws of the State of Israel (“Kadimastem”) with a principal address located at |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.5 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.4 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.1 PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Warrant Shares: [] Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [] or its assigns (the “Holder”) |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.7 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
Exhibit 10.10 AMENDED AND RESTATED RESEARCH AND LICENCE AGREEMENT This Amended and Restated Research and Licence Agreement (“Agreement”) is entered into on 7 May 2013, and is effective as of 29 October 2009 (“the Effective Date”) Between HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. a company duly incorporated and existing under the laws of the State of Israel of P.O. Box 12000 Jerusalem |
|
| March 3, 2025 |
Exhibit 10.11 [PARENT], [ADDRESS] Confidential [Director] [Company] [Address] [Company] [Address] Zurich, [Date] 2025 Re: Indemnification Agreement Dear [Director], In consideration of your prior and continuing service in your capacity as member of the board of directors (the “Board”) of (i) [Company], [Address], with company register no. CHE-[…], (ii) [Company], [Address], with company register n |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.8 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
Exhibit 10.7 FEASIBILITY STUDY AGREEMENT THIS FEASIBILITY STUDY AGREEMENT (the “Agreement”) is entered into effect on September 9, 2018 (the “Effective Date”) PARTIES 1. Kadimastem Ltd., a public company registered under the laws of Israel, with offices at 7 Sapir St., Weizmann Science Park, Ness-Ziona 74140, Israel (“Kadimastem”) 2. Australian Foundation for Diabetes Research ACN 97 097 263 824 ( |
|
| March 3, 2025 |
RESEARCH AND LICENSE AGREEMENT Exhibit 10.8 RESEARCH AND LICENSE AGREEMENT This Research and License Agreement (“Agreement”) is made this 22nd day of January, 2015 (the “Effective Date”), by and between: RAMOT AT TEL AVIV UNIVERSITY LTD. of P.O.B. 39296, Tel-Aviv 6139001, Israel (“Ramot”), on the first part; and KADIMASTEM LTD., of 7 Sapir St., Weizmann Science Park, Ness-Ziona 74140, Israel; (the “Company”), of the second part |
|
| February 27, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform Zürich, Switzerland – February 27, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), in collaboration with Aexon Labs Inc. ( “Aexon Labs”), is pleased to announce new preclinical findings on AEX-2, rein |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| February 25, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission file number: 001-39957 |
|
| February 25, 2025 |
Exhibit 99.1 Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, February 25, 2025. NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimast |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| February 14, 2025 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares, par value CHF 0.02 per share, of NLS Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to |
|
| February 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) NLS Pharmaceutics Ltd. |
|
| February 10, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-39957 NLS PHARMACEUT |
|
| February 10, 2025 |
As filed with the Securities and Exchange Commission on February 10, 2025 As filed with the Securities and Exchange Commission on February 10, 2025 Registration No. |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offi |
|
| February 10, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies ● Revolutionizing Diabetes Treatment: Introduction of cutting-edge, multi-targeted innovation to transform diabetes care. ● Diabetes more than just a Metabolic Disorder: Diabetes is a multi-systemic disease impacting the central nervous system (CNS), immune function, and cellula |
|
| February 5, 2025 |
As filed with the Securities and Exchange Commission on February 4, 2025 As filed with the Securities and Exchange Commission on February 4, 2025 Registration No. |
|
| February 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) NLS Pharmaceutics Ltd. |
|
| January 31, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 7) Commission file number: 001-39957 |
|
| January 31, 2025 |
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics Exhibit 99.1 Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL — January 31, 2025 / NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (“Kadimastem”) (TASE |
|
| January 31, 2025 |
TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 AMENDMENT TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment, dated January 30, 2025 (this “Amendment”) to the Agreement of Merger and Plan of Reorganization dated November 4, 2024 (the “Agreement”) between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“Kadimastem”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzer |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 8) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 30, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting Zurich, Switzerland – January 30, 2025 – NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 28, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence ● Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths - with 90% involving synthetic opioids like fentanyl ● Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associate |
|
| January 28, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 5) Commission file number: 001-39957 |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 16, 2025 |
Exhibit 99.1 Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS Kadimastem Approaches Final Steps for Securing Merger Completion ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 16th 2025 — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 16, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 4) Commission file number: 001-39957 |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 8, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file number: 001-39957 |
|
| January 8, 2025 |
Exhibit 99.1 NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 8, 2025 — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offic |
|
| December 30, 2024 |
Consent of Moore Financial Consulting Exhibit 99.5 Letter of consent December 2024 23/12/2024 Consent of Moore Financial Consulting We hereby consent to the use of our opinion letter dated December 19, 2024 to Kadimastem Ltd. (“Kadimastem”) included as an Annex to the Proxy Statement/Prospectus, which forms a part of the Registration Statement of Kadimastem on Form F-4 relating to the proposed merger of Kadimastem and NLS Pharmaceutic |
|
| December 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) NLS Pharmaceutics Ltd. |
|
| December 30, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 7) Commission file number: 001-39957 |
|
| December 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on December 27, 2024. As filed with the U.S. Securities and Exchange Commission on December 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction of incorporation or or |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 30, 2024 |
Exhibit 99.1 NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, December 30 |
|
| December 23, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 23 December 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invi |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 6) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 4) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland ( |
|
| December 19, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 16 December 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invi |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 19, 2024 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment ● This submission comes after successful INTERACT meeting with the FDA earlier this year. ● NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND an |
|
| December 19, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 5) Commission file number: 001-39957 |
|
| December 17, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 16 December 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invi |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 4) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 11, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission file number: 001-39957 |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 11, 2024 |
Exhibit 99.1 NLS Pharmaceutics CEO Issues Letter to Shareholders Zürich, Switzerland, December 11, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of princip |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 4, 2024 |
Exhibit 99.3 NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at an Approximate 15% Premium to the Market ZURICH, SWITZERLAND / ACCESSWIRE / December 4, 2024 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients |
|
| December 4, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 4, 2024, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purch |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offi |
|
| December 3, 2024 |
Exhibit 99.1 NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders Zürich, Switzerland, December 3, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential of its dual |
|
| November 25, 2024 |
NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland November 25, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: NLS Pharmaceutics Ltd. (CIK: 0001783036) Registration Statement on Form F-3 (File No. 333-282788) (the “Registration Statement”) Request for Accelera |
|
| November 21, 2024 |
NLSP / NLS Pharmaceutics AG / Hafner Ronald - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0221253-13ga2hafnernls.htm AMENDMENT NO. 2 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) (Rule 13d-102) Under the Securities Exchange Act of 1934 NLS Pharmaceutics Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) H57830103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statem |
|
| November 18, 2024 |
Exhibit 99.1 NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders Zürich, Switzerland, November 18, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovativ |
|
| November 18, 2024 |
NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland November 18, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill and Joe McCann Re: NLS Pharmaceutics Ltd. Registration Statement on Form F-3 Filed October 23, 2024 File No. 333-282788 Dear Ms. Hamill and Mr. McCann: The p |
|
| November 18, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024 As filed with the Securities and Exchange Commission on November 18, 2024 Registration No. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 15, 2024 |
Exhibit 99.1 STATUTEN ARTICLES OF ASSOCIATION der of NLS Pharmaceutics AG NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics SA NLS Pharmaceutics Ltd NLS Pharmaceutics Ltd (die “Gesellschaft”) (the “Company”) I. Firma, Sitz, Dauer und Zweck der Gesellschaft I. Name, Domicile, Duration and Purpose of the Company Art. 1 - Firma, Sitz, Dauer Art. 1 - Name, Domicile, Duration Unter der Firma |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 14, 2024 |
NLSP / NLS Pharmaceutics AG / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NLS Pharmaceuticals Ltd. (Name of Issuer) Common Shares, par value CHF 0.02 per share (Title of Class of Securities) H57830137 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares, par value CHF 0.02 per share, of NLS Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to |
|
| November 14, 2024 |
NLSP / NLS Pharmaceutics AG / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-nlsp093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NLS PHARMACEUTICS LTD. (Name of Issuer) Common shares, nominal value CHF 0.02 per share (Title of Class of Securities) H57830137 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 12, 2024 |
Kadimastem Ltd. Interim Financial Statements as of June 30, 2024 Table of Contents Exhibit 99.2 Kadimastem Ltd. Interim Financial Statements as of June 30, 2024 Unaudited Table of Contents Page Statements of Financial Position 2 Statements of Profit or Loss and Other Comprehensive Income 3 Statements of Changes in Equity 4-6 Statements of Cash Flows 7-8 Notes to the Financial Statements 9-16 KADIMASTEM LTD. STATEMENTS OF FINANCIAL POSITION June 30, December 31, 2024 2023 2023 Un |
|
| November 12, 2024 |
Kadimastem Ltd. Financial Statements as of December 31, 2023 Table of Contents Exhibit 99.1 Kadimastem Ltd. Financial Statements as of December 31, 2023 Table of Contents Page Report of Independent Registered Public Accounting Firm 2 Statements of Financial Position 3 Statements of Profit or Loss and Other Comprehensive Income 4 Statements of Changes in Equity 5-7 Statements of Cash Flows 8-9 Notes to the Financial Statements 10-66 - - - - - - - - - - - - - - - - 1 Kost Fore |
|
| November 12, 2024 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The following information and all other information contained in these Unaudited Pro Forma Combined Financial Statements reflects a notice of a reverse split with the commercial registry of the Canton of Zurich, Switzerland, on September 27, 2024 that became effective in Switzerland on September 27, 2024. The reverse stock split was at |
|
| November 12, 2024 |
Exhibit 99.4 Kost Forer Gabbay & Kasierer 144A Derech Menachem Begin Tel Aviv 6492102 Tel.: +972-3-6232525 Fax: +972-3-5622555 ey.com November 11, 2024 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following registration statements: (1) Registration Statement (Form F-3 No. 333-262489) of NLS Pharmaceutics Ltd. (2) Registration Statemen |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 (Report No. 3) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 6, 2024 |
Exhibit 99.1 Category: Notifications issued to company members Sub-category: Invitation to the General Meeting Publication date: SHAB 18.10.2024 Publicly viewable until: 18.12.2024 Publication number: UP04-0000006582 Publishing entity Wenger Vieli AG, Dufourstrasse 56, 8008 Zürich Invitation to the extraordinary general meeting NLS Pharmaceutics AG Organisation concerned: NLS Pharmaceutics AG CHE- |
|
| November 5, 2024 |
Exhibit 99.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between NLS PHARMACEUTICS LTD., and VSTOCK TRANSFER, LLC, as the Rights Agent Dated as of , 2024 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated , 2024, is by and between, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS”), and VStock Transfer, LLC, a California limited liability company, as Rights Ag |
|
| November 5, 2024 |
Exhibit 99.3 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”), dated as of , 2024 (the “Effective Date”), by and among NLS Pharmaceutics Ltd. (the “Company”), a corporation incorporated under the laws of Switzerland, and certain the shareholders of the Company listed on Schedule A hereto (each, a “Shareholder” and, collectively, the “Shareholders”). RECITALS WHEREA |
|
| November 5, 2024 |
Exhibit 99.1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG NLS Pharmaceutics LTD. NLS PHARMACEUTICS (ISRAEL) LTD. and KADIMASTEM LTD. DATED AS OF NOVEMBER 4, 2024 CONTENTS Page Article I THE MERGER 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 Articles of Association 3 1.5 Effects of the Merger 3 1.6 Officers and Directors 3 Article II EFFECTS OF MERGER ON SHARE CAPITAL; EX |
|
| November 5, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-39957 |
